DellaCamera owns 6.4% of Nabi Biopharmaceuticals

By Lisa Kerner

Charlotte, N.C., Feb. 29 - Investors led by DellaCamera Capital Master Fund, Ltd. upped their stake in Nabi Biopharmaceuticals to 6.4% from 5.1% with the purchase of an additional 234,278 shares of the company's stock.

The shares were purchased between Jan. 31 and Feb. 22 priced from $3.37 to $3.57, according to a schedule 13D filing with the Securities and Exchange Commission.

The investors beneficially own 3,358,838 shares of the Boca Raton, Fla., pharmaceutical company.

On Jan. 31, DellaCamera suggested Nabi pay a special dividend or begin a "substantial" Dutch tender if the company's previously announced strategic review process fails to result in a transaction that is neither a sale nor a merger.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.